Verseon Corporation Verseon presents new DME efficacy results

TIDMVSN

Verseon Corporation

02 October 2017

Press release October 2, 2017

Verseon Corporation

("Verseon" or the "Company")

Verseon presents new efficacy results in diabetic macular edema program at Targeting Ocular Disorders conference

Fremont, Calif.-Verseon, a technology-based pharmaceutical company employing a computer-driven platform to develop a diverse drug pipeline, presented promising preclinical efficacy results on its plasma kallikrein inhibitors for the treatment of diabetic macular edema (DME) at the Targeting Ocular Disorders conference in Boston last week. By developing drugs for either eye-drop or oral administration, the Company aims to provide much-needed alternatives to the current standard of recurring intravitreal injections (anti-VEGF agents or corticosteroids) and laser treatments.

When administered as single eye drops in intraocular pharmacokinetic studies, a number of Verseon's plasma kallikrein inhibitors reach significant concentrations in the relevant tissues of the eye. Other candidates show good oral exposure and bioavailability.

At the Targeting Ocular Disorders conference, Verseon's Dr. Timothy Shiau reported on a comprehensive in vivo efficacy model in which the Company's drug candidates reduce leakage into the retina and restore mean circulation times. In addition to previously disclosed results showing efficacy after infusion-pump dosing, Dr. Shiau presented new data demonstrating that certain Verseon inhibitors are efficacious when dosed orally. Both preclinical findings firmly establish that Verseon's drug candidates successfully slow the progression of DME.

"Plasma kallikrein inhibitors are promising candidates for slowing and potentially reversing DME," said Dr. Shiau. "We are excited about our recent results, which show that within our novel class of plasma kallikrein inhibitors, we have multiple candidates with excellent profiles for topical ophthalmic administration and others suitable for oral dosing."

About Verseon's diabetic macular edema program

Verseon has developed a new class of potent, selective compounds for the treatment of diabetic macular edema. The Company's plasma kallikrein inhibitors target a validated pathway addressing an underlying cause of the disease. In preclinical testing, Verseon's inhibitors show favorable biochemical properties permitting either topical (eye drop) or oral administration. Several lead candidates have demonstrated efficacy after infusion pump dosing, while others are efficacious when administered orally.

About Verseon

Verseon Corporation (www.verseon.com, AIM: VSN) is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

-Ends-

For further information, please contact

 
 Verseon Corporation                www.verseon.com 
                                    +1 (510) 225 
 Tina Schlafly                       9000 
 
 Cenkos Securities (NOMAD and 
  Joint Broker) 
                                     +44 (0) 20 
 Neil McDonald / Beth McKiernan       7397 8900 
 
 Cantor Fitzgerald Europe (Joint 
  Broker) 
 Marc Milmo / Phil Davies /         +44 (0) 20 
  Callum Butterfield                 7894 7000 
 
 Mirabaud Securities LLP (Joint 
  Broker) 
                                    +44 (0) 20 
 Peter Krens                         7321 2508 
 

For financial and business media enquiries, please contact

 
 Buchanan Communications Ltd 
  (PR Advisers) 
 Henry Harrison-Topham / Jamie    +44 (0) 20 
  Hooper                           7466 5000 
 

For trade and pharma media enquiries, please contact

 
 Vane Percy & Roberts 
                         +44 (0) 1737 
 Simon Vane Percy         821 890 
 

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends, " "estimates," "plans," "will," "outlook," and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions, and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAMBBBTMBMMTIR

(END) Dow Jones Newswires

October 02, 2017 02:00 ET (06:00 GMT)